Riskpilot← Back to searchSign inGet full accessEQL Pharma AB
ABActiveOrg 5567133425Stortorget 1 1trWholesale of pharmaceutical and medical goods · NACE 4646Est. 200620-49 employees
Revenue 2025
SEK 371,9M
+44% vs 2024
EBITDA margin
18.0%
+117% vs 2024
Equity ratio
15.3%
Financial strength
Net profit 2025
SEK 12,9M
+752% vs 2024
| Revenue | SEK 371,9M | +44% |
| EBITDA | SEK 67,1M | +117% |
| Net profit | SEK 12,9M | +752% |
| Total assets | SEK 802M | +117% |
| Equity | SEK 122,7M | +12% |
| Employees | — | — |
Legal name
EQL Pharma AB
Org number
5567133425
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
19 oktober 2006
Share capital
SEK 1 308 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Schörling, Axel Nils-Ingvar i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Schörling, Axel Nils-Ingvar i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolagets verksamhet skall vara att tillverka, utveckla, idka handel med medicinska-, diagnostiska-, farmaceutiska- och kemisk- tekniska produkter, förvärva och upplåta licenser och agenturer för sådana produkter samt därmed förenlig verksamhet. Bolaget ska även idka finansiell verksamhet, dock inte sådan verksamhet som avses i bankrörelselagen eller lagen om kreditmarknadsbolag.
Address
Stortorget 1 1tr
Email
anna.jonsson@eqlpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 24 698 | 43 748 | 67 788 | 173 944 | 406 049 | 254 333 | 258 167 | 371 910 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 5 603 | 5 185 | −1 603 | 2 932 | 8 220 | 28 073 | 38 464 | 41 119 | 30 844 | 67 050 |
| Depreciation & amort. | −1 331 | −1 362 | −1 690 | −4 552 | −3 858 | −17 120 | — | — | — | — |
| EBIT | 4 272 | 3 823 | −3 293 | −1 620 | 4 362 | 10 953 | 38 464 | 41 119 | 30 844 | 67 050 |
| Net financials | −550 | −8 | −2 | −88 | −432 | −1 004 | −2 779 | −2 293 | −3 948 | −13 489 |
| Profit before tax | 3 722 | 3 815 | −895 | −1 709 | 2 930 | 9 949 | 16 005 | 476 | 1 946 | 16 244 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −114 | −438 | −3 392 |
| Net profit | 3 722 | 3 815 | −895 | −1 709 | 2 930 | 9 949 | 16 005 | 362 | 1 508 | 12 852 |
| Item | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 52 786 | 63 164 | 65 986 | 100 721 | 123 086 | 197 432 | 232 739 | 281 781 | 370 283 | 801 956 |
| Equity | 47 085 | 57 225 | 56 306 | 77 582 | 80 513 | 90 462 | 107 324 | 107 879 | 109 652 | 122 698 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 12 600 | 7 200 | 0 | 15 453 | 338 387 |
| Short-term debt | 5 701 | 5 939 | 9 681 | 23 139 | 42 573 | 94 370 | 98 215 | 115 402 | 160 178 | 217 871 |
| Total debt | 5 701 | 5 939 | 9 681 | 23 139 | 42 573 | 106 970 | 105 415 | 115 402 | 175 631 | 556 258 |
EBITDA margin
18.0%
This company
15.8%
Market median
+14% vs market
20152025
Equity ratio
15.3%
This company
38.2%
Market median
-60% vs market
20152025
Return on equity
10.5%
This company
18.4%
Market median
+43% vs market
20152025
Net profit margin
3.5%
This company
8.1%
Market median
-57% vs market
20152025
Asset turnover
0.46×
This company
1.12×
Market median
-59% vs market
20152025
Debt / equity
5.54×
This company
0.62×
Market median
-794% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-01-01 – 2018-03-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Chief Auditor | Chief Auditor | 2022 | — | — |
AN Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
HO Auditor Substitute | Auditor Substitute | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EQL Pharma AB 
EQL PHARMA OYBoard members of EQL Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Axel Nils-Ingvar Schörling | Chief Executive Officer | 0 companies |
| Hans Ola Brorsson | Auditor Substitute | 0 companies |
| Per Olof Svangren | Board of Directors | 0 companies |
| Lars Christer Fredrik Fåhraeus | Chairman | 0 companies |
| Lars John Anders Månsson | Board of Directors | 0 companies |
| Nikunj Ajitbhai Shah | Board of Directors | 0 companies |
| Gustav Ingemar Kihlström | Chairman | 0 companies |
| Lars Holmqvist | Board of Directors | 0 companies |
| Eva Maria Bech | Board of Directors | 0 companies |
| Ingrid Linda Marie Neckmar | Board of Directors | 0 companies |
| Björn Allan Beermann | Board of Directors | 0 companies |
| Per-Erik Ollermark | Board of Directors | 0 companies |
| Rajiv Indravadan Modi | Board of Directors | 0 companies |
| Raymond Gopal De Vré | Board of Directors | 0 companies |